Luke Evnin sold $2,546 of HOWL
director, owner at Werewolf Therapeutics, Inc.. 2,425 shares at an average of $1.05, traded Mar 27, 2025, filed Apr 30, 2025.
Score components
- +15RoleDirector
- 0Trade size$3k at market
- 0Share of holdings soldSold 0.1% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +34.1%, 3m +33.0%, 6m +72.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-011570, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 27, 2025 | XIn-the-money exercise Common Stockindirect: See Footnote | +28,113 | $0.09 | $2,530 | 4,312,285 | Apr 30, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -2,425 | $1.05 | $2,546 | 4,309,860 | Apr 30, 2025 |
| Mar 27, 2025 | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: See Footnote | -4,015 | $0.00 | $0 | 0 | Apr 30, 2025 |
| Mar 27, 2025 | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: See Footnote | -24,098 | $0.00 | $0 | 0 | Apr 30, 2025 |
Related signals
Other insiders at Werewolf Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $45k 143,199 shares | -100% | |
| 29Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $47k 157,084 shares | -52% | |
| 31Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $146k 416,911 shares | -9% | |
| 31Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $174k 448,836 shares | -9% | |
| 38Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $254k 678,226 shares | -12% | |
| 13Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $28k 76,928 shares | -20% | |
| 14Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $43k 105,565 shares | -22% | |
| 16Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $64k 139,803 shares | -22% | |
| 16Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $66k 141,106 shares | -18% | |
| 17Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $87k 191,762 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.